pyroglutamate rongliflozin

Pyroglutamate rongliflozin appears to be a salt or derivative of the SGLT2 inhibitor "rongliflozin" (also known as ertugliflozin), specifically the L-pyroglutamic acid salt form. SGLT2 inhibitors are a class of oral antidiabetic drugs that lower blood glucose by inhibiting sodium-glucose co-transporter 2 in the kidney, thereby increasing urinary glucose excretion. The addition of "pyroglutamate" indicates this is a specific formulation or salt form, which may affect properties like solubility or stability but does not change the core mechanism of action. Ertugliflozin and its derivatives are primarily indicated for type 2 diabetes mellitus to improve glycemic control.

Other names

pyroglutamate rongliflozin